From: Implementation status of pharmacological studies in the development of orphan drugs
BRAF | in vitro | In vivo | Clinical trial (Phase III) | ||||
---|---|---|---|---|---|---|---|
Kinase inhibition | Inhibition of cell phosphorylation | Growth inhibition | Inclusion criteria | Vemurafenib (n = 336) | Control (n = 337) | ||
V600E mutation | 〇 | 〇 | 〇 | 〇 | 〇 | 295(88%) | 303(90%) |
V600D mutation | 〇 | 〇 | 〇 | △a | 0 | 1 | |
V600K mutation | 〇 | △a | 33(10%) | 24(7%) | |||
Other mutations | 10 other V600 mutations | V600R mutation | 0 | 1 | |||
Wild type | 〇 | 〇 | 〇 | 1 | 1 |